Clinical trial · no report yet · Phase 3
NCT03941860
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
- NCT03941860 ↗
- Completed
- National Cancer Institute (NCI)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Multiple Myeloma
- Interventions
- Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Computed Tomography; Ixazomib Citrate; Lenalidomide; Placebo Administration; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm A (lenalidomide, ixazomib citrate) · Experimental
- Arm B (lenalidomide, placebo) · Placebo comparator
- Enrollment
- 1
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 16, 2022
- Primary completion
- Aug 6, 2023
- Results posted
- Yes
- Registry record
- NCT03941860 · updated May 23, 2025